SCHEMBL25192522

SCHEMBL25192522

N#Cc1cc(F)cc(N2CCN(Cc3cnc4cc(C5CC5)c(=O)[nH]c4c3)CC2)c1

nearest known ligand 0.70

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 20/20 0.70
▸ PARP2 Q9UGN5 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30413482 1.00 PARP1 (0.70) PARP1PARP2
SCHEMBL25188028 0.84 PARP1 (0.78) PARP1
SCHEMBL24649721 0.84 PARP1 (0.79) PARP1PARP2
SCHEMBL25187130 0.83 PARP1 (0.74) PARP1
SCHEMBL30893586 0.82 PARP1 (1.00) PARP1PARP2
SCHEMBL25188780 0.82 PARP1 (1.00) PARP1PARP2
SCHEMBL26152809 0.81 PARP1 (0.65) PARP1PARP2
SCHEMBL25187661 0.79 PARP1 (0.76) PARP1PARP2
SCHEMBL25188309 0.79 PARP1 (1.00) PARP1PARP2
SCHEMBL30511342 0.79 PARP1 (1.00) PARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289800-A1 Selective Parp1 Inhibitor And Application Thereof KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2025-09-18 — — US disclosed
EP-4434985-A1 SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) 2024-09-25 — — EP disclosed
CN-118055933-A Selective PARP1 inhibitors and uses thereof 成都百裕制药股份有限公司 2024-05-17 — — CN disclosed
WO-2023088408-A1 SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF 成都百裕制药股份有限公司 2023-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289800-A1 Selective Parp1 Inhibitor And Application Thereof PARP1, PARP11, PARP12 PARP1 1/4885PARP2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback